In @Buckland 's defence, there was talk of another company who managed to do a deal before the PAA option was not taken up.
Only the inner sanctum of VM knows whether the prior deal had anything to do with rejection of PAA. Did it bring VM to saturation point given the merger? Was it superior (clinically, financially, time to first revenue, etc?) To get straight answers from VM here would be very nice, but I doubt they will ever come to light
- Forums
- ASX - By Stock
- Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints
In @Buckland 's defence, there was talk of another company who...
-
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
18.0¢ |
Change
0.005(2.86%) |
Mkt cap ! $85.12M |
Open | High | Low | Value | Volume |
18.0¢ | 18.0¢ | 18.0¢ | $18 | 100 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 152309 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 329759 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 152309 | 0.175 |
16 | 432906 | 0.170 |
8 | 260593 | 0.165 |
8 | 396304 | 0.160 |
6 | 336734 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 329759 | 3 |
0.185 | 302471 | 6 |
0.190 | 726823 | 8 |
0.195 | 579857 | 11 |
0.200 | 312726 | 12 |
Last trade - 10.06am 12/09/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |